nach oben

01.02.2009 | Review Article

Current Considerations in the Treatment of Generalized Anxiety Disorder

verfasst von: Dr Martin A. Katzman

Erschienen in: CNS Drugs | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Generalized anxiety disorder (GAD) is a chronic disorder that frequently co-occurs with a variety of co-morbidities in patients with somatic conditions and other mental disorders. GAD is highly prevalent and is one of the most common anxiety disorders seen by primary care physicians. The individual and societal cost associated with GAD is high and the marked level of impairment experienced by patients with this disorder is equivalent in magnitude to that reported in patients with major depressive disorder. Furthermore, patients with GAD are at risk of suicide or suicide attempts, and are frequent users of healthcare services. Thus, GAD is a serious and chronic condition that requires appropriate long-term treatment.

The focus of acute treatment for patients with GAD is the improvement of symptoms, while the primary goal of long-term clinical management is remission, i.e. the complete resolution of both symptoms and functional impairment. The consensus across current treatment guidelines is that first-line treatment for patients with GAD should consist of an antidepressant, either a selective serotonin reuptake inhibitor (SSRI) such as sertraline, paroxetine or escitalopram, or a selective serotonin noradrenaline (norepinephrine) reuptake inhibitor (SNRI) such as venlafaxine or duloxetine. However, the SSRIs and SNRIs have efficacy limitations, such as lack of response in many patients, a 2- to 4-week delay before the onset of symptom relief, lack of full remission, and risk of relapse. In addition, there are troublesome adverse effects associated with both the SSRIs and SNRIs.

Evidence from early clinical studies of the atypical antipsychotics in the treatment of anxiety and GAD indicate that they may have a potential role in the treatment of GAD, either as monotherapy or as augmentation to standard treatment.

Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593–602PubMedCrossRef

Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 2002; 16: 162–71PubMedCrossRef

Riedel M, Muller N, Strassnig M, et al. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci 2005; 255: 432–7PubMedCrossRef

Ansseau M, Fischler B, Dierick M, et al. Prevalence and impact of generalized anxiety disorder and major depression in primary care in Belgium and Luxemburg: the GADIS study. Eur Psychiatry 2005; 20: 229–35PubMedCrossRef

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed., revised. Washington, DC. American Psychiatric Association, 1987

Katon W, Von Korff M, Lin E, et al. Distressed high utilizers of medical care. DSM-III-R diagnoses and treatment needs. Gen Hosp Psychiatry 1990; 12: 355–62

Chartier M, Walker J, Kjernisted K. Health care utilization and anxiety disorders. Anxiety Disorders Association of America. 20th National Conference; 2000 Mar 23–26; Washington, DC

Keller MB. The long-term clinical course of generalized anxiety disorder. J Clin Psychiatry 2002; 63Suppl. 8: 11–6PubMed

Wittchen HU, Zhao S, Kessler RC, et al. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 355–64PubMedCrossRef

10.

Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol 2005; 15: 445–52PubMedCrossRef

11.

Culpepper L. Generalized anxiety disorder in primary care: emerging issues in management and treatment. J Clin Psychiatry 2002; 63Suppl. 8: 35–42PubMed

12.

Moffitt TE, Caspi A, Harrington H, et al. Generalized anxiety disorder and depression: childhood risk factors in a birth cohort followed to age 32. Psychol Med 2008; 37: 441–52CrossRef

13.

Biederman J, Rosenbaum JF, Hirshfeld DR, et al. Psychiatric correlates of behavioral inhibition in young children of parents with and without psychiatric disorders. Arch Gen Psychiatry 1990; 47: 21–6PubMedCrossRef

14.

Manassis K, Bradley S, Goldberg S, et al. Behavioural inhibition, attachment and anxiety in children of mothers with anxiety disorders. Can J Psychiatry 1995; 40: 87–92PubMed

15.

Rosenbaum JF, Biederman J, Gersten M, et al. Behavioral inhibition in children of parents with panic disorder and agoraphobia: a controlled study. Arch Gen Psychiatry 1988; 45: 463–70PubMedCrossRef

16.

Rosenbaum JF, Biederman J, Bolduc EA, et al. Comorbidity of parental anxiety disorders as risk for childhood-onset anxiety in inhibited children. Am J Psychiatry 1992; 149: 475–81PubMed

17.

Schwartz CE, Snidman N, Kagan J. Adolescent social anxiety as an outcome of inhibited temperament in childhood. J Am Acad Child Adolesc Psychiatry 1999; 38: 1008–15PubMedCrossRef

18.

Wittchen HU, Kessler RC, Pfister H, et al. Why do people with anxiety disorders become depressed? A prospective-longitudinal community study. Acta Psychiatr Scand Suppl 2000; 406: 14–23PubMedCrossRef

19.

Wittchen HU, Beesdo K, Bittner A, et al. Depressive episodes: evidence for a causal role of primary anxiety disorders? Eur Psychiatry 2003; 18: 384–93PubMedCrossRef

20.

Kessler RC, Andrade LH, Bijl RV, et al. The effects of comorbidity on the onset and persistence of generalized anxiety disorder in the ICPE surveys. International Consortium in Psychiatric Epidemiology. Psychol Med 2002; 32: 1213–25

21.

Judd LL, Kessler RC, Paulus MP, et al. Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS). Acta Psychiatr Scand Suppl 1998; 393: 6–11PubMedCrossRef

22.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994

23.

Carter RM, Wittchen HU, Pfister H, et al. One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample. Depress Anxiety 2001; 13: 78–88PubMedCrossRef

24.

Hasler G, Pine DS, Gamma A, et al. The associations between psychopathology and being overweight: a 20-year prospective study. Psychol Med 2004; 34: 1047–57PubMedCrossRef

25.

Stein DJ. Comorbidity in generalized anxiety disorder: impact and implications. J Clin Psychiatry 2001; 62Suppl. 11: 29–34PubMed

26.

Simon NM, Otto MW, Wisniewski SR, et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2004; 161: 2222–9PubMedCrossRef

27.

Henning ER, Turk CL, Mennin DS, et al. Impairment and quality of life in individuals with generalized anxiety disorder. Depress Anxiety 2007; 24: 342–9PubMedCrossRef

28.

Frisch MB, Cornell J, Villaneuva M, et al. Clinical validation of the Quality of Life Inventory: a measure of life satisfaction for use in treatment planning and outcome assessment. Psychol Assess 1992; 4: 92–101CrossRef

29.

Wittchen HU, Carter RM, Pfister H, et al. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol 2000; 15: 319–28PubMedCrossRef

30.

Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA 1989; 262: 914–9PubMedCrossRef

31.

Kessler RC, DuPont RL, Berglund P, et al. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 1999; 156: 1915–23PubMed

32.

Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress Anxiety 2008; 25: 72–90PubMedCrossRef

33.

Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 473–83

34.

Bernal M, Haro JM, Bernert S, et al. Risk factors for suicidality in Europe: Results from the ESEMED study. J Affect Disord 2006; 101: 27–34PubMedCrossRef

35.

Bruce SE, Machan JT, Dyck I, et al. Infrequency of “pure” GAD: impact of psychiatric comorbidity on clinical course. Depress Anxiety 2001; 14: 219–25PubMedCrossRef

36.

Hettema JM, Kuhn JW, Prescott CA, et al. The impact of generalized anxiety disorder and stressful life events on risk for major depressive episodes. Psychol Med 2006; 36: 789–95PubMedCrossRef

37.

Nutt D, Argyropoulos S, Hood S, et al. Generalized anxiety disorder: a comorbid disease. Eur Neuropsycho-pharmacol 2006; 16Suppl. 2: S109–18CrossRef

38.

Wittchen HU, Kessler RC, Beesdo K, et al. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 2002; 63Suppl. 8: 24–34PubMed

39.

Wittchen HU, Nelson CB, Lachner G. Prevalence of mental disorders and psychosocial impairments in adolescents and young adults. Psychol Med 1998; 28: 109–26PubMedCrossRef

40.

Lim D, Sanderson K, Andrews G. Lost productivity among full-time workers with mental disorders. J Ment Health Policy Econ 2000; 3: 139–46PubMedCrossRef

41.

Marciniak MD, Lage MJ, Dunayevich E, et al. The cost of treating anxiety: the medical and demographic correlates that impact total medical costs. Depress Anxiety 2005; 21: 178–84PubMedCrossRef

42.

Smit F, Cuijpers P, Oostenbrink J, et al. Costs of nine common mental disorders: implications for curative and preventive psychiatry. J Ment Health Policy Econ 2006; 9: 193–200PubMed

43.

Souetre E, Lozet H, Cimarosti I, et al. Cost of anxiety disorders: impact of comorbidity. J Psychosom Res 1994; 38Suppl. 1: 151–60PubMedCrossRef

44.

Lothgren M. Economic evidence in anxiety disorders: a review. Eur J Health Econ 2004; 5Suppl. 1: S20–5PubMedCrossRef

45.

Buhr K, Dugas MJ. The Intolerance of Uncertainty Scale: psychometric properties of the English version. Behav Res Ther 2002; 40: 931–45PubMedCrossRef

46.

Dugas MJ, Marchand A, Ladouceur R. Further validation of a cognitive-behavioral model of generalized anxiety disorder: diagnostic and symptom specificity. J Anxiety Disord 2005; 19: 329–43PubMedCrossRef

47.

Canadian Psychiatric Association. Management of anxiety disorders. Can J Psychiatry 2006; 51Suppl. 2: 1–93S

48.

World Health Organization. International statistical classification of diseases. 10th rev. Vol. 3. Geneva: World Health Organization, 1992

49.

World Health Organization. International statistical classification of diseases. 10th rev. Vol. 3, 2nd rev. Geneva: World Health Organization, 2005

50.

Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50–5PubMedCrossRef

51.

Ruscio AM, Chiu WT, Roy-Byrne P, et al. Broadening the definition of generalized anxiety disorder: effects on prevalence and associations with other disorders in the National Comorbidity Survey Replication. J Anxiety Disord 2007; 21: 662–76PubMedCrossRef

52.

Argyropoulos SV, Ploubidis GB, Wright T, et al. Development and validation of the Generalized Anxiety Disorder Inventory (GADI). J Psychopharmacol 2007; 21: 145–52PubMedCrossRef

53.

Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166: 1092–7PubMedCrossRef

54.

Meyer TJ, Miller ML, Metzger RL, et al. Development and validation of the Penn State Worry Questionnaire. Behav Res Ther 1990; 28: 487–95PubMedCrossRef

55.

Ballenger JC. Overview of different pharmacotherapies for attaining remission in generalized anxiety disorder. J Clin Psychiatry 2001; 62Suppl. 19: 11–9PubMed

56.

Gorman JM, Hirschfeld RM, Ninan PT. New developments in the neurobiological basis of anxiety disorders. Psychopharmacol Bull 2002; 36Suppl. 2: 49–67PubMed

57.

Weizman R, Tanne Z, Granek M, et al. Peripheral benzo-diazepine binding sites on platelet membranes are increased during diazepam treatment of anxious patients. Eur J Pharmacol 1987; 138: 289–92PubMedCrossRef

58.

Rocca P, Beoni AM, Eva C, et al. Peripheral benzodiazepine receptor messenger RNA is decreased in lymphocytes of generalized anxiety disorder patients. Biol Psychiatry 1998; 43: 767–73PubMedCrossRef

59.

Varnas K, Halldin C, Hall H. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp 2004; 22: 246–60PubMedCrossRef

60.

Nutt DJ. Antidepressants in panic disorder: clinical and preclinical mechanisms. J Clin Psychiatry 1998; 59Suppl. 8: 24–8PubMed

61.

Scherrer JF, True WR, Xian H. Evidence for genetic influences common and specific to symptoms of generalized anxiety and panic. J Affect Disord 2000; 57: 25–35PubMedCrossRef

62.

Hettema JM, Prescott CA, Kendler KS. A population-based twin study of generalized anxiety disorder in men and women. J Nerv Ment Dis 2001; 189: 413–20PubMedCrossRef

63.

Kendler KS, Gardner CO, Gatz M, et al. The sources of co-morbidity between major depression and generalized anxiety disorder in a Swedish national twin sample. Psychol Med 2007; 37: 453–62PubMedCrossRef

64.

Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders. World J Biol Psychiatry 2002; 3: 171–99PubMedCrossRef

65.

Baldwin SH, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005; 19: 567–96PubMedCrossRef

66.

NICE guidelines. Anxiety: management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. London: National Institute for Health and Clinical Excellence, 2004 Dec

67.

Rickels K, Rynn M, Iyengar M, et al. Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. J Clin Psychiatry 2006; 67: 41–7PubMedCrossRef

68.

Guy W. Clinical global impressions. In: Guy W, editor. ECDEU assessment manual for psychopharmacology. Rockville (MD): US National Institute of Health, 1976: 218–22

69.

Rickels K, Zaninelli R, McCafferty J, et al. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2003; 160: 749–56PubMedCrossRef

70.

Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001; 62: 350–7PubMedCrossRef

71.

Hewett K, Adams A, Bryson H, et al. Generalised anxiety disorder: efficacy of paroxetine [poster]. 7th World Congress of Biological Psychiatry; 2001 Jul 1–6; Berlin

72.

Stocchi F, Nordera G, Jokinen RH, et al. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 2003; 64: 250–8PubMedCrossRef

73.

Davidson JR, Bose A, Korotzer A, et al. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety 2004; 19: 234–40PubMedCrossRef

74.

Allgulander C, Florea I, Huusom AK. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 2006; 9: 495–505PubMedCrossRef

75.

Brawman-Mintzer O, Knapp RG, Rynn M, et al. Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006; 67: 874–81PubMedCrossRef

76.

Allgulander C, Dahl AA, Austin C, et al. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry 2004; 161: 1642–9PubMedCrossRef

77.

Ball SG, Kuhn A, Wall D, et al. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. J Clin Psychiatry 2005; 66: 94–9PubMedCrossRef

78.

Gelenberg AJ, Lydiard RB, Rudolph RL, et al. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA 2000; 283: 3082–8PubMedCrossRef

79.

Nimatoudis I, Zissis NP, Kogeorgos J, et al. Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder: a double-blind, randomized, placebo controlled study. Int Clin Psychopharmacol 2004; 19: 331–6PubMedCrossRef

80.

Lenox-Smith AJ, Reynolds A. A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. Br J Gen Pract 2003; 53: 772–7PubMed

81.

Eli Lilly and Company. Study suggests Cymbalta® significantly reduces core anxiety symptoms of generalised anxiety disorder, 2006 Mar 24 [online]. Available from URL: http://www.prnewswire.com [Accessed 2008 Nov 13]

82.

Allgulander C, Hartford J, Russell J, et al. Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials. Curr Med Res Opin 2007; 23(6): 1245–52PubMedCrossRef

83.

Hartford J, Kornstein S, Liebowitz M, et al. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 2007; 22: 167–74PubMedCrossRef

84.

Lauer D, Holzel L, Hornyak M. Generalized anxiety disorder with comorbidity: treatment with pregabalin [in German]. Nervenarzt 2006; 77(11): 1363–7PubMedCrossRef

85.

Frampton JE, Foster RH. Pregabalin: in the treatment of generalised anxiety disorder. CNS Drugs 2006; 20: 685–93PubMedCrossRef

86.

Montgomery SA, Tobias K, Zornberg GL, et al. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 2006; 67: 771–82PubMedCrossRef

87.

Chessick CA, Allen MH, Thase M, et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev 2006; (3): CD006115

88.

Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67: 361–70PubMedCrossRef

89.

Davidson JR, DuPont RL, Hedges D, et al. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 1999; 60: 528–35PubMedCrossRef

90.

Pollack MH, Worthington JJ, Manfro GG, et al. Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone. J Clin Psychiatry 1997; 58Suppl. 11: 19–23PubMed

91.

Struzik L, Vermani M, Coonerty-Femiano A, et al. Treatments for generalized anxiety disorder. Expert Rev Neurother 2004; 4: 285–94PubMedCrossRef

92.

Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993; 50: 884–95PubMedCrossRef

93.

Roerig JL. Diagnosis and management of generalized anxiety disorder. J Am Pharm Assoc 1999; 39: 811–21

94.

Pollack MH. Optimizing pharmacotherapy of generalized anxiety disorder to achieve remission. J Clin Psychiatry 2001; 62Suppl. 19: 20–5PubMed

95.

Kennedy SH, Lam RW, Cohen NL, et al. Clinical guidelines for the treatment of depressive disorders: IV. Medications and other biological treatments. Can J Psychiatry 2001; 46Suppl. 1: 38–58S

96.

Gahimer J, Wernicke J, Yalcin I, et al. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin 2007; 23: 175–84PubMedCrossRef

97.

Thase ME. Treatment of anxiety disorders with venlafaxine XR. Expert Rev Neurother 2006; 6: 269–82PubMedCrossRef

98.

Himei A, Okamura T. Discontinuation syndrome associated with paroxetine in depressed patients: a retrospective analysis of factors involved in the occurrence of the syndrome. CNS Drugs 2006; 20: 665–72PubMedCrossRef

99.

Perahia DG, Kajdasz DK, Desaiah D, et al. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. J Affect Disord 2005; 89: 207–12PubMedCrossRef

100.

Joint Formulary Committee. British national formulary. 52nd ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2006

101.

FDA Public Health Advisory. Suicidality in children and adolescents being treated with antidepressant medications, 2004 Oct 15 [online]. Available from URL: http://www.fda.gov/cder/drug/antidepressants/SSRIPHA20040.htm [Accessed 2008 Nov 13]

102.

FDA. FDA proposes new warnings about suicidal thinking, behavior in young adults who take antidepressant medications [online]. Available from URL: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01624.html [Accessed 2008 Sep 25]

103.

Tiihonen J, Lonnqvist J, Wahlbeck K, et al. Anti-depressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 2006; 63: 1358–67PubMedCrossRef

104.

Lang AJ. Treating generalized anxiety disorder with cognitive-behavioral therapy. J Clin Psychiatry 2004; 65Suppl. 13: 14–9PubMed

105.

Hunot V, Churchill R, Silva DL, et al. Psychological therapies for generalised anxiety disorder. Cochrane Database Syst Rev 2007; (1): CD001848

106.

Borkovec TD, Ruscio AM. Psychotherapy for generalized anxiety disorder. J Clin Psychiatry 2001; 62Suppl. 11: 37–42PubMed

107.

Chambless DL, Gillis MM. Cognitive therapy of anxiety disorders. J Consult Clin Psychol 1993; 61: 248–60PubMedCrossRef

108.

Borkovec TD, Whisman MA. Psychosocial treatment for generalized anxiety disorder. In: Mavissakalian MR, Prien RF, editors. Long-term treatments of anxiety disorders. Washington (DC): American Psychiatric Press, 1996: 171–99

109.

Arntz A. Cognitive therapy versus applied relaxation as treatment of generalized anxiety disorder. Behav Res Ther 2003; 41: 633–46PubMedCrossRef

110.

Stanley MA, Beck JG, Novy DM, et al. Cognitive-behavioral treatment of late-life generalized anxiety disorder. J Consult Clin Psychol 2003; 71: 309–19PubMedCrossRef

111.

Mohlman J, Gorenstein EE, Kleber M, et al. Standard and enhanced cognitive-behavior therapy for late-life generalized anxiety disorder: two pilot investigations. Am J Geriatr Psychiatry 2003; 11: 24–32PubMed

112.

Worthington III JJ, Kinrys G, Wygant LE, et al. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 2005; 20: 9–11PubMedCrossRef

113.

Galynker I, Khan A, Grebchenko Y, et al. Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression. J Clin Psychiatry 2005; 66: 544PubMedCrossRef

114.

Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 2005; 66: 1321–5PubMedCrossRef

115.

Pollack MH, Simon NM, Zalta AK, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry 2006; 59: 211–5PubMedCrossRef

116.

Brawman-Mintzer O, Nietert PJ, Rynn M, et al. Quetiapine monotherapy in patients with GAD [abstract no. NR634]. American Psychiatric Association 159th Annual Meeting; 2006 May 20–25; Toronto (ON)

117.

Katzman M, Vermani M, Jacobs L, et al. The use of quetiapine as an adjunct in the pharmacotherapy of generalised anxiety disorder: a flexible-dose, open-label trial [poster]. 7th International Forum on Mood and Anxiety Disorders; 2007 Dec 5–7; Budapest

118.

Snyderman SH, Rynn MA, Rickels K. Open-label pilot study of ziprasidone for refractory generalized anxiety disorder. J Clin Psychopharmacol 2005; 25: 497–9PubMedCrossRef

119.

Crane DL. Ziprasidone as an augmenting agent in the treatment of anxiety-spectrum disorders. CNS Spectr 2005; 10: 176–9PubMed

120.

Simon NM, Hoge EA, Fischmann D, et al. An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry 2006; 67: 381–5PubMedCrossRef

121.

Reiss S, Peterson RA, Gursky M, et al. Anxiety sensitivity, anxiety frequency and the prediction of fearfulness. Behav Res Ther 1986; 24: 1–8PubMedCrossRef

122.

Morin CM. Insomnia: psychological assessment and management. New York (NY): Guilford, 1993

123.

Hedlund JL, Viewig BW. Hamilton rating scale for depression: a comprehensive review. J Oper Psychiatry 1979; 10: 149–65

124.

Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–9PubMedCrossRef

125.

Buysse DJ, Reynolds III CF, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28: 193–213PubMedCrossRef

126.

Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993; 29: 321–6PubMed

127.

Sheehan DV. The anxiety disease. New York (NY): Charles Scribner’s Sons, 1983

128.

Leon AC, Shear MK, Portera L, et al. Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Soc Psychiatry Epidemiol 1992; 27: 78–82CrossRef

129.

Calabrese JR, Keck Jr PE, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 1351–60PubMedCrossRef

130.

Thase M, MacFadden W, McCoy R, et al. Efficacy of quetiapine monotherapy in bipolar depression: a confirmatory double-blind, placebo-controlled study (the BOLDER II Study). Int J Neuropsychopharmacol 2006; 9: S237

131.

Carson WH, Kitagawa H, Nemeroff CB. Drug development for anxiety disorders: new roles for atypical anti-psychotics. Psychopharmacol Bull 2004; 38Suppl. 1: 38–45

132.

Masand PS, Narasimhan M. Improving adherence to anti-psychotic pharmacotherapy. Curr Clin Pharmacol 2006; 1:47–56PubMedCrossRef

133.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980

134.

Bremner JD. Traumatic stress: effects on the brain. Dialogues Clin Neurosci 2006; 8: 445–61PubMed

135.

Bremner JD. Stress and brain atrophy. CNS Neurol Disord Drug Targets 2006; 5: 503–12PubMedCrossRef

136.

Zhang L, Zhou R, Li X, et al. Stress-induced change of mitochondria membrane potential regulated by genomic and non-genomic GR signaling: a possible mechanism for hippocampus atrophy in PTSD. Med Hypotheses 2006; 66: 1205–8PubMedCrossRef

137.

Kalisch R, Schubert M, Jacob W, et al. Anxiety and hippocampus volume in the rat. Neuropsychopharmacology 2006; 31: 925–32PubMedCrossRef

138.

Ballenger JC. Treatment of anxiety disorders to remission. J Clin Psychiatry 2001; 62Suppl. 12: 5–9PubMed

139.

Rector NA, Szacun-Shimizu K, Leybman M. Anxiety sensitivity within the anxiety disorders: disorder-specific sensitivities and depression comorbidity. Behav Res Ther 2007; 45(8): 1967–75PubMedCrossRef

Titel: Current Considerations in the Treatment of Generalized Anxiety Disorder
verfasst von: Dr Martin A. Katzman
Publikationsdatum: 01.02.2009
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 2/2009
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200923020-00002

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen